Similarly, the NCI Formulary, a partnership between NCI and biotechnology and pharmaceutical companies
to improve
access to otherwise proprietary experimental
drugs, has so far enabled about a dozen pharmaceutical and biotech companies
to work through thorny negotiations on intellectual property, licensing, and other issues,
to speed research and clinical testing.